Merck & Co Inc - Company Profile
Powered by
All the data and insights you need on Merck & Co Inc in one report.
- Save hours of research time and resources with
our up-to-date Merck & Co Inc Strategy Report
- Understand Merck & Co Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreMerck & Co Inc (Merck) is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors, and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
Merck & Co Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Vaccine: | Zetia |
Influenza Virus Vaccine | Vytorin |
BCG Vaccine | Integrilin |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Regulatory Approval | In April, the company secured approval from Health Canada for Keytruda (pembrolizumab) in combination with fluoropyrimidine and platinum-containing chemotherapy to treat adult gastric cancer patients. |
2024 | Contracts/Agreements | In April, the company signed a clinical trial collaboration and supply agreement with Hanmi Pharmaceutical to commence a phase 1 clinical trial to estimate the safety and efficacy of BH3120 in combination with KEYTRUDA. |
2024 | Contracts/Agreements | In April, the company entered into a partnership with BioMed X to develop innovative immunotherapeutic strategies targeting the immunosuppressive microenvironment of solid tumors. |
Competitor Comparison
Key Parameters | Merck & Co Inc | Johnson & Johnson | Pfizer Inc | AbbVie Inc | Sanofi |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | France |
City | Kenilworth | New Brunswick | New York | North Chicago | Paris |
State/Province | New Jersey | New Jersey | New York | Illinois | Ile-de-France |
No. of Employees | 72,000 | 131,900 | 88,000 | 50,000 | 87,994 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Robert M. Davis | Chairman; Chief Executive Officer; President | Executive Board | 2022 | 57 |
Caroline Litchfield | Chief Financial Officer; Executive Vice President | Senior Management | 2021 | 55 |
Michael Klobuchar | Chief Strategy Officer; Executive Vice President | Senior Management | 2021 | - |
Cristal N. Downing | Chief Communications & Public Affairs Officer; Executive Vice President | Senior Management | 2021 | - |
David M. Williams | Chief Information and Digital Officer; Executive Vice President | Senior Management | 2020 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer